Yining Ye

3.6k total citations
32 papers, 703 citations indexed

About

Yining Ye is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Yining Ye has authored 32 papers receiving a total of 703 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 10 papers in Oncology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Yining Ye's work include Fibroblast Growth Factor Research (9 papers), Lung Cancer Treatments and Mutations (5 papers) and CAR-T cell therapy research (4 papers). Yining Ye is often cited by papers focused on Fibroblast Growth Factor Research (9 papers), Lung Cancer Treatments and Mutations (5 papers) and CAR-T cell therapy research (4 papers). Yining Ye collaborates with scholars based in United States, Spain and Germany. Yining Ye's co-authors include John D. Kalbfleisch, Douglas E. Schaubel, Keith A. Delman, Neil Senzer, Robert S. Coffin, Thomas Amatruda, Frances A. Collichio, Robert Hans Ingemar Andtbacka, Jason Chesney and Lynn E. S̄pitler and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Yining Ye

31 papers receiving 685 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yining Ye United States	14	235	155	147	132	99	32	703
Haocheng Li Canada	18	394 1.7×	68 0.4×	382 2.6×	262 2.0×	51 0.5×	58	1.1k
Lars Beckmann Germany	16	156 0.7×	31 0.2×	343 2.3×	67 0.5×	309 3.1×	36	898
Jianchang Lin United States	18	395 1.7×	276 1.8×	293 2.0×	359 2.7×	8 0.1×	84	1.0k
Serena G. Liao United States	9	130 0.6×	31 0.2×	243 1.7×	94 0.7×	57 0.6×	19	526
Min Jin Ha United States	15	239 1.0×	33 0.2×	325 2.2×	119 0.9×	51 0.5×	51	655
Peter Salzman United States	15	211 0.9×	22 0.1×	246 1.7×	91 0.7×	54 0.5×	28	653
Anil Prasad United States	11	222 0.9×	23 0.1×	465 3.2×	62 0.5×	77 0.8×	18	836
Claire S. Zhu United States	7	108 0.5×	54 0.3×	161 1.1×	90 0.7×	29 0.3×	10	503
Navdeep Pal United States	11	189 0.8×	55 0.4×	91 0.6×	127 1.0×	47 0.5×	26	689
H. Rauschecker Germany	15	345 1.5×	102 0.7×	135 0.9×	98 0.7×	61 0.6×	43	742

Countries citing papers authored by Yining Ye

Since Specialization

Citations

This map shows the geographic impact of Yining Ye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yining Ye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yining Ye more than expected).

Fields of papers citing papers by Yining Ye

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yining Ye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yining Ye. The network helps show where Yining Ye may publish in the future.

Co-authorship network of co-authors of Yining Ye

This figure shows the co-authorship network connecting the top 25 collaborators of Yining Ye. A scholar is included among the top collaborators of Yining Ye based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yining Ye. Yining Ye is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ye, Yining, Yujia Qin, Xin Cong, et al.. (2024). DebugBench: Evaluating Debugging Capability of Large Language Models. 4173–4198. 16 indexed citations

Ye, Yining, et al.. (2024). A Study on the Mechanical Behavior of a Wind Turbine Foundation with a Constrained Structural Shear Connector. Buildings. 14(10). 3162–3162. 1 indexed citations

Ye, Yining, Zhong Zhang, Yujia Qin, et al.. (2024). RepoAgent: An LLM-Powered Open-Source Framework for Repository-level Code Documentation Generation. 436–464. 13 indexed citations

Ye, Yining & Jennifer E. Arnold. (2023). Learning the statistics of pronoun reference: By word or by category?. Cognition. 239. 105546–105546. 2 indexed citations

Jahchan, Nadine S., et al.. (2023). Expansion, Persistence and Pharmacodynamic Profile of ADI-001, a First-in-Class Allogeneic CD20-Targeted CAR Gamma Delta T Cell Therapy, in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma. Blood. 142(Supplement 1). 3478–3478. 7 indexed citations

Pal, Sumanta K., Siamak Daneshmand, Surena F. Matin, et al.. (2020). PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring FGFR3 alterations.. Journal of Clinical Oncology. 38(6_suppl). TPS600–TPS600. 5 indexed citations

Makawita, Shalini, Robin Kate Kelley, Sameek Roychowdhury, et al.. (2020). Circulating free DNA (cfDNA) and tissue next-generation sequencing analysis in a phase II study of infigratinib (BGJ398) for cholangiocarcinoma with FGFR2 fusions.. Journal of Clinical Oncology. 38(4_suppl). 579–579. 1 indexed citations

Javle, Milind, Ivan Borbath, Stephen Clarke, et al.. (2019). Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial.. Journal of Clinical Oncology. 37(15_suppl). TPS4155–TPS4155. 15 indexed citations

Javle, Milind, Robin Kate Kelley, Sameek Roychowdhury, et al.. (2019). AB051. P-19. A phase II study of infigratinib (BGJ398) in previously-treated advanced cholangiocarcinoma containing FGFR2 fusions. HepatoBiliary Surgery and Nutrition. 8(S1). AB051–AB051. 16 indexed citations

10.

Li, Gary, Melanie A. Krook, Sameek Roychowdhury, et al.. (2019). Abstract 2206: Anti-tumor activity of infigratinib, a potent and selective inhibitor of FGFR1, FGFR2 and FGFR3, in FGFR fusion-positive cholangiocarcinoma and other solid tumors. 2206–2206. 1 indexed citations

11.

Bass, Michael, Bin Yao, Yong-Jiang Hei, et al.. (2014). Challenges in Developing a Validated Biomarker for Angiogenesis Inhibitors: The Motesanib Experience. PLoS ONE. 9(10). e108048–e108048. 5 indexed citations

12.

Kaufman, Howard L., Robert Hans Ingemar Andtbacka, Frances A. Collichio, et al.. (2014). Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.. Journal of Clinical Oncology. 32(15_suppl). 9008a–9008a. 36 indexed citations

13.

Andtbacka, Robert Hans Ingemar, Frances A. Collichio, Thomas Amatruda, et al.. (2013). OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.. Journal of Clinical Oncology. 31(15_suppl). LBA9008–LBA9008. 91 indexed citations

14.

Kalbfleisch, John D., Douglas E. Schaubel, Yining Ye, & Qi Gong. (2013). An Estimating Function Approach to the Analysis of Recurrent and Terminal Events. Biometrics. 69(2). 366–374. 27 indexed citations

15.

Boer, Richard H. De, Dusan Kotasek, Shane White, et al.. (2012). Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer. Breast Cancer Research and Treatment. 135(1). 241–252. 11 indexed citations

16.

Ye, Yining & Bin Yao. (2012). Demonstrating Biosimilarity via Equivalence in Clinical Trials. Statistics in Biopharmaceutical Research. 4(3). 264–272. 2 indexed citations

17.

Teodorescu, Mihaela, Flavia B. Consens, William F. Bria, et al.. (2008). Predictors of Habitual Snoring and Obstructive Sleep Apnea Risk in Patients With Asthma. CHEST Journal. 135(5). 1125–1132. 93 indexed citations

18.

Blumenschein, George R., Alan Sandler, Timothy J. O’Rourke, et al.. (2007). PD3-3-7: Safety and Pharmacokinetics (PK) of AMG 706 With Carboplatin/Paclitaxel (C/P) and/or Panitumumab for the treatment of patients with advanced non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 2(8). S469–S469. 7 indexed citations

19.

Ye, Yining, John D. Kalbfleisch, & Douglas E. Schaubel. (2007). Semiparametric Analysis of Correlated Recurrent and Terminal Events. Biometrics. 63(1). 78–87. 107 indexed citations

20.

Wells, Rebecca, Christy Harris Lemak, Jeffrey A. Alexander, et al.. (2007). Do licensing and accreditation matter in outpatient substance abuse treatment programs?. Journal of Substance Abuse Treatment. 33(1). 43–50. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact